Ufenamate
Based on 1 Customer Validation
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.89%
- CAS. Nr.: 67330-25-0
- Formel: C18H18F3NO2
- Molecular Weight:337.34
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Pyroptosis Compound Library
HY-L059
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Osteogenesis Compound Library
HY-L131
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Lactylation Compound Library
HY-L249
Biologische Aktivität
|
COX-2 |
Ufenamate (Ointment application, single dose) has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging mice model and downregulates the expression level of COX-2[3].
Ufenamat (Ointment application, 6 and 8 weeks) promotes the healing of skull injuries in mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:UV-induced acute sunburn model, photoaging model and skin squamous cell carcinoma model in SKH-1 hairless mice[3]
-
Dosage:Ointment application
-
Administration:Ointment application; single dose; 30 min
-
Result:Inhibited acute swelling and redness caused by UV irradiation and reduced COX-2 expression.
At 12 weeks of irradiation, skin aging was alleviated, the collagen density of the dermis was higher, the expression of Bcl-2 was weakened, and the expression of Bax and Caspase 3 was enhanced.
At 28 weeks of irradiation, the appearance of tumors was delayed.
-
Animal Model:Intact and damaged skin of rats[2]
-
Dosage:2µL/cm2
-
Administration:Ointment application; single dose
-
Result:Applied on the damaged skin, contained in the epidermis was approximately 50% and 25% of that in the intact skin after LP and water, respectively, with the content being 5 times and 10 times higher than in the intact skin.
Permeated UF five times more than LP in the intact skin. Reduced significantly the permeation of UF by both LP and water due to the defatting effect of SC.
-
Animal Model:Skull defect mice[4]
-
Dosage:Ointment application
-
Administration:Ointment application; 6 weeks and 8 weeks
-
Result:Promoted the formation of new bone in the defect area, and the effect was stronger after 8 weeks than at 6 weeks, improving the BV/TV and BMD in the defect area.
Chemical Information
-
CAS. Nr. 67330-25-0
-
Appearance Liquid (Density: 1.2230 g/cm3)
-
Molecular Weight 337.34
-
Formel C18H18F3NO2
-
Color Colorless to light yellow
-
SMILES
O=C(OCCCC)C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2
-
Synonyms
Flufenamic acid butyl ester; Butyl flufenamate
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : ≥ 44 mg/mL (130.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Iino H, et al. Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles. Biol Pharm Bull. 2015;38(10):1645-8. [Content Brief]
[2]. Hayato Iino, et al. Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles. Bio Pharm Bull. 2015;38(10):1645-8. [Content Brief]
[4]. Fan Yang, et al. Topical Application of Butyl Flufenamate Ointment Promotes Cranial Defect Healing in Mice by Inducing BMP2 Secretion in Skin Mesenchymal Stem Cells. Cells. 2022 Nov 15;11(22):3620. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9644 mL | 14.8218 mL | 29.6437 mL | 74.1092 mL |
| 5 mM | 0.5929 mL | 2.9644 mL | 5.9287 mL | 14.8218 mL | |
| 10 mM | 0.2964 mL | 1.4822 mL | 2.9644 mL | 7.4109 mL | |
| 15 mM | 0.1976 mL | 0.9881 mL | 1.9762 mL | 4.9406 mL | |
| 20 mM | 0.1482 mL | 0.7411 mL | 1.4822 mL | 3.7055 mL | |
| 25 mM | 0.1186 mL | 0.5929 mL | 1.1857 mL | 2.9644 mL | |
| 30 mM | 0.0988 mL | 0.4941 mL | 0.9881 mL | 2.4703 mL | |
| 40 mM | 0.0741 mL | 0.3705 mL | 0.7411 mL | 1.8527 mL | |
| 50 mM | 0.0593 mL | 0.2964 mL | 0.5929 mL | 1.4822 mL | |
| 60 mM | 0.0494 mL | 0.2470 mL | 0.4941 mL | 1.2352 mL | |
| 80 mM | 0.0371 mL | 0.1853 mL | 0.3705 mL | 0.9264 mL | |
| 100 mM | 0.0296 mL | 0.1482 mL | 0.2964 mL | 0.7411 mL |
Ufenamate Related Classifications
HY-100009 Related Classifications
Powered by Bioz